← Back to Search

Other

Novel Spectacle Lenses for Near-sightedness (CYPRESS Trial)

N/A
Waitlist Available
Research Sponsored by SightGlass Vision, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the safety and efficacy of a new spectacle lens design in reducing the progression of juvenile myopia (nearsightedness). The trial will last 36 months and will include three groups of participants.

Who is the study for?
This trial is for children aged 6-10 with near-sightedness, having a specific range of short-sighted prescription (-0.75 to -4.50 D). They must not have more than a 1.50 D difference between their eyes and be willing to participate for 3 years without wearing contact lenses.
What is being tested?
The study tests new spectacle lens designs meant to slow down the worsening of near-sightedness in kids. It's a masked, three-group comparison lasting for three years where neither participants nor observers know who gets which type of glasses.
What are the potential side effects?
Since this trial involves wearing special glasses, side effects are minimal but may include discomfort with fit or vision changes as the child adapts to the new lens design.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Axial length
Spherical equivalent refraction

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Test Arm 3Experimental Treatment1 Intervention
Single vision, impact-resistant spectacle lenses
Group II: Test Arm 2Experimental Treatment1 Intervention
Single vision, impact-resistant spectacle lenses
Group III: Test Arm 1Experimental Treatment1 Intervention
Single vision, impact-resistant spectacle lenses
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Spectacle lenses
2022
N/A
~80
Novel spectacle lens design
2022
N/A
~60

Find a Location

Who is running the clinical trial?

SightGlass Vision, Inc.Lead Sponsor
10 Previous Clinical Trials
827 Total Patients Enrolled
Joseph Rappon, OD, MS, FAAOStudy ChairSightGlass Vision, Inc.
1 Previous Clinical Trials
50 Total Patients Enrolled

Media Library

Novel spectacle lens design (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03623074 — N/A
Nearsightedness Research Study Groups: Test Arm 3, Test Arm 2, Test Arm 1
Nearsightedness Clinical Trial 2023: Novel spectacle lens design Highlights & Side Effects. Trial Name: NCT03623074 — N/A
Novel spectacle lens design (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03623074 — N/A
~36 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top